Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
3 hedge funds and large institutions have $2K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
33% less capital invested
Capital invested by funds: $3K → $2K (-$1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$702 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$67 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $2K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| – | +$67 | +2,000 | +367% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | +$702 | +20,817 | +144% |
|
EYEGW Hedge Fund Activity: Q2 2019 in Review
3 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q2 2019, worth a combined $2K — down 33% from $3K a quarter earlier.
Fund positioning in EYEGW was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $702.
- 3 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $2K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q2 2019, down 33% quarter-over-quarter.
- 0 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q2 2019 and 0 closed out.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q2 2019 was Susquehanna International Group, an estimated $702 added.
Based on aggregated 13F filings for Q2 2019.